EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CXCR4: from B-cell development to B cell–mediated diseases

Stéphane Giorgiutti iD, Julien Rottura, Anne-Sophie Korganow, Vincent Gies iD

Life Science Alliance · 2024-06 · 7 (6) · e202302465

DOI: 10.26508/lsa.202302465 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life Science Alliance, online erschienen am 22.03.2024. Verfasst von Stéphane Giorgiutti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for P…. Hauptthemen laut MEDLINE: Immunologic Deficiency Syndromes, Agammaglobulinemia, Warts. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemokine receptors are members of the G protein–coupled receptor superfamily. The C-X-C chemokine receptor type 4 (CXCR4), one of the most studied chemokine receptors, is widely expressed in hematopoietic and immune cell populations. It is involved in leukocyte trafficking in lymphoid organs and inflammatory sites through its interaction with its natural ligand CXCL12. CXCR4 assumes a pivotal role in B-cell development, ranging from early progenitors to the differentiation of antibody-secreting cells. This review emphasizes the significance of CXCR4 across the various stages of B-cell development, including central tolerance, and delves into the association between CXCR4 and B cell–mediated disorders, from immunodeficiencies such as WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome to autoimmune diseases such as systemic lupus erythematosus. The potential of CXCR4 as a therapeutic target is discussed, especially through the identification of novel molecules capable of modulating specific pockets of the CXCR4 molecule. These insights provide a basis for innovative therapeutic approaches in the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunologic Deficiency SyndromesAgammaglobulinemiaWartsHumansB-LymphocytesReceptors, CXCR4

Substanzen

Receptors, CXCR4CXCR4 protein, human

Autor:innen und Institutionen

  • Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiency, Strasbourg University Hospital, Strasbourg, F…
  • INSERM UMR - S1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantex NG, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg…
  • Faculty of Medicine, Université de Strasbourg, Strasbourg, France.
  • Faculty of Pharmacy, Université de Strasbourg, Illkirch, France.

ORCID-Profile: Stéphane Giorgiutti, Vincent Gies

Förderung

  • Agence Nationale de la Recherche

Zitieren

APA

Giorgiutti, S., Rottura, J., Korganow, A. S., & Gies, V. (2024). CXCR4: from B-cell development to B cell–mediated diseases. Life Science Alliance, 7(6), e202302465. https://doi.org/10.26508/lsa.202302465

Vancouver

Giorgiutti S, Rottura J, Korganow AS, Gies V. CXCR4: from B-cell development to B cell–mediated diseases. Life Science Alliance. 2024;7(6):e202302465. doi:10.26508/lsa.202302465

BibTeX
@article{Giorgiutti2024,
  author = {Giorgiutti, Stéphane and Rottura, Julien and Korganow, Anne-Sophie and Gies, Vincent},
  title = {CXCR4: from B-cell development to B cell–mediated diseases},
  journal = {Life Science Alliance},
  year = {2024},
  volume = {7},
  number = {6},
  pages = {e202302465},
  doi = {10.26508/lsa.202302465}
}
Kostenlos starten →